Organon & Co. (OGN) Projected to Post Earnings on Thursday

Organon & Co. (NYSE:OGN) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $0.74 per share and revenue of $1.5152 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.93 by $0.08. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. During the same period last year, the firm earned $1.38 EPS. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Price Performance

NYSE:OGN opened at $8.29 on Thursday. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. Organon & Co. has a 52 week low of $6.18 and a 52 week high of $17.23. The business’s 50-day simple moving average is $7.85 and its two-hundred day simple moving average is $8.69. The stock has a market cap of $2.16 billion, a PE ratio of 4.32, a P/E/G ratio of 1.71 and a beta of 0.58.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th were given a dividend of $0.02 per share. The ex-dividend date was Thursday, November 20th. This represents a $0.08 annualized dividend and a dividend yield of 1.0%. Organon & Co.’s dividend payout ratio (DPR) is presently 4.17%.

Hedge Funds Weigh In On Organon & Co.

A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new position in shares of Organon & Co. during the second quarter worth approximately $107,000. NorthRock Partners LLC bought a new position in Organon & Co. in the third quarter worth approximately $115,000. Quadrant Capital Group LLC purchased a new position in Organon & Co. during the 3rd quarter worth $116,000. Gamco Investors INC. ET AL purchased a new stake in Organon & Co. in the second quarter valued at about $119,000. Finally, Cresset Asset Management LLC purchased a new stake in Organon & Co. in the second quarter valued at about $134,000. 77.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on OGN. Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Barclays started coverage on Organon & Co. in a research note on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price objective on the stock. JPMorgan Chase & Co. decreased their price target on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 11th. Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a research report on Monday, October 27th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Organon & Co. currently has an average rating of “Reduce” and an average price target of $8.38.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.